MAM
TBPH icon

Meeder Asset Management’s Theravance Biopharma TBPH Stock Holding History

Meeder Asset Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-172
Closed -$2K – 2206
2020
Q3 		$2K Sell
172
-497
-74% -$9.31K ﹤0.01% 1873
2020
Q2 		$15K Sell
669
-397
-37% -$10.2K ﹤0.01% 1212
2020
Q1 		$25K Buy
1,066
+229
+27% +$5.73K ﹤0.01% 1161
2019
Q4 		$22K Buy
+837
New +$16.3K ﹤0.01% 1321
2017
Q2 		– Sell
-296
Closed -$11K – 1864
2017
Q1 		$11K Buy
+296
New +$9.46K ﹤0.01% 841

Other funds holding TBPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Meeder Asset Management's TBPH Position: Q4 2020 in Review

Meeder Asset Management sold out of Theravance Biopharma (TBPH) in Q4 2020, closing a stake of 172 shares — an estimated $2K sold.

Meeder Asset Management first reported a position in TBPH in Q1 2017 and held it in 5 quarters. The position peaked at $25K in Q1 2020. 107 funds tracked by Wall St. Rank hold TBPH as of Q4 2020.

  • Meeder Asset Management reported no remaining Theravance Biopharma position as of Q4 2020 after selling out during the quarter.
  • Meeder Asset Management sold 172 Theravance Biopharma shares in Q4 2020, an estimated $2K.
  • Meeder Asset Management first reported a position in Theravance Biopharma in Q1 2017 and held it in 5 quarters.
  • Meeder Asset Management's Theravance Biopharma position peaked at $25K in Q1 2020.
  • 107 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2020.

Based on Meeder Asset Management's 13F filing for Q4 2020, filed 9 Feb 2021.